Role of Interleukin 6 in Epithelial Hyperproliferation and Bone Resorption in Middle Ear Cholesteatomas

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 1996 Jan 1

PMID 8652157

Citations 4

Authors

J Bujia

C Kim

P Ostos

E Kastenbauer

L Hultner

Affiliations

Soon will be listed here.

Abstract

Locally produced pro-inflammatory cytokines are considered to play an important role in the initiation and/or maintenance of inflammatory diseases. In cholesteatomatous lesions there are increased levels of some cytokines and inflammatory mediators like interleukin 1, tumor necrosis factor and colony-stimulating factor, etc. Interleukin 6 (IL-6) can be produced by different cells present in cholesteatoma (e.g. keratinocytes, lymphocytes, fibroblasts and macrophages). Until now, no data have been available on the role of IL-6 in cholesteatoma. In this study we used immunohistochemistry to investigate the presence and distribution of IL-6 in tissue samples from cholesteatoma patients. Levels of the cytokine were quantified in tissue extracts using an enzyme-linked immunosorbent assay. Finally, the presence of biologically active IL-6 was analyzed in the murine cell line 7TD1. Human skin samples obtained from the external ear canal were used as controls. Using the anti-IL-6 antibody in an alkaline phosphatase anti alkaline phosphatase technique, a moderate diffuse staining of the whole epidermis was observed in sections of normal skin. In cryostat sections of cholesteatoma samples, a stronger staining of the whole epithelium was observed. Many of the cells infiltrating the cholesteatoma stroma also showed positive immunostainings. The concentration of IL-6 in relation to the total protein concentration in cholesteatoma (119.33 +/- 30) were higher than in human skin (9.16 +/- 13). While IL-6 activity was not detected in skin samples, two of the ten cholesteatoma samples studied showed a stimulatory effect when incubated with the cell line 7TD1. The overexpression of IL-6 in middle ear cholesteatoma suggests a participation of this cytokine in some of the clinical features seen: epithelial hyperproliferation and bone resorption. The absence of biological activity in the majority of the cholesteatoma samples points to the presence of natural inhibitors for IL-6.

Citing Articles

Increased Acquired Cholesteatoma Risk in Patients with Osteoporosis: A Retrospective Cohort Study.

Wang T, Lin C, Lin C, Chung H, Wang C, Tsai M PLoS One. 2015; 10(7):e0132447.

PMID: 26171780 PMC: 4501779. DOI: 10.1371/journal.pone.0132447.

The c-MYC protooncogene expression in cholesteatoma.

Palko E, Poliska S, Csakanyi Z, Katona G, Karosi T, Helfferich F Biomed Res Int. 2014; 2014:639896.

PMID: 24683550 PMC: 3934790. DOI: 10.1155/2014/639896.

Some considerations about acquired adult and pediatric cholesteatomas.

Dornelles C, Da Costa S, Meurer L, Schweiger C Braz J Otorhinolaryngol. 2006; 71(4):536-45.

PMID: 16446973 PMC: 9441961. DOI: 10.1016/s1808-8694(15)31212-x.

Interleukin 1 (IL-1) and IL-1-receptor antagonist (IL-1-RA) in middle ear cholesteatoma: an analysis of protein production and biological activity.

Bujia J, Kim C, Ostos P, Sudhoff H, Kastenbauer E, Hultner L Eur Arch Otorhinolaryngol. 1996; 253(4-5):252-5.

PMID: 8737779 DOI: 10.1007/BF00171137.

References

Yellon R, Leonard G, Marucha P, Sidman J, Carpenter R, Burleson J . Demonstration of interleukin 6 in middle ear effusions. Arch Otolaryngol Head Neck Surg. 1992; 118(7):745-8. DOI: 10.1001/archotol.1992.01880070075014. View

Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y . Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine. 1990; 2(5):381-7. DOI: 10.1016/1043-4666(90)90069-6. View

Bujia J, Schilling V, Holly A, STAMMBERGER M, Kastenbauer E . Hyperproliferation-associated keratin expression in human middle ear cholesteatoma. Acta Otolaryngol. 1993; 113(3):364-8. DOI: 10.3109/00016489309135826. View

Sehgal P . Interleukin-6: molecular pathophysiology. J Invest Dermatol. 1990; 94(6 Suppl):2S-6S. DOI: 10.1111/1523-1747.ep12874963. View

Schulz P, Bujia J, Holly A, Shilling V, Kastenbauer E . Possible autocrine growth stimulation of cholesteatoma epithelium by transforming growth factor alpha. Am J Otolaryngol. 1993; 14(2):82-7. DOI: 10.1016/0196-0709(93)90044-8. View

Yan S, Huang C . Lymphotoxin in human middle ear cholesteatoma. Laryngoscope. 1991; 101(4 Pt 1):411-5. DOI: 10.1002/lary.1991.101.4.411. View

Wong G, Clark S . Multiple actions of interleukin 6 within a cytokine network. Immunol Today. 1988; 9(5):137-9. DOI: 10.1016/0167-5699(88)91200-5. View

Content J, De Wit L, Poupart P, Opdenakker G, Van Damme J, Billiau A . Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor. Eur J Biochem. 1985; 152(2):253-7. DOI: 10.1111/j.1432-1033.1985.tb09191.x. View

Ishimi Y, Miyaura C, Jin C, Akatsu T, Abe E, Nakamura Y . IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990; 145(10):3297-303. View

10.

Huang T, Yan S, Huang C . Colony-stimulating factor in middle ear cholesteatoma. Am J Otolaryngol. 1989; 10(6):393-8. DOI: 10.1016/0196-0709(89)90034-3. View

11.

Prens E, Benne K, Van Damme J, Bakkus M, Brakel K, Benner R . Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol. 1990; 95(6 Suppl):121S-124S. DOI: 10.1111/1523-1747.ep12874991. View

12.

Ahn J, Huang C, Abramson M . Third place--Resident Basic Science Award 1990. Interleukin 1 causing bone destruction in middle ear cholesteatoma. Otolaryngol Head Neck Surg. 1990; 103(4):527-36. DOI: 10.1177/019459989010300403. View

13.

Black K, Garrett I, Mundy G . Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991; 128(5):2657-9. DOI: 10.1210/endo-128-5-2657. View

14.

Hultner L, Moeller J . Mast cell growth-enhancing activity (MEA) stimulates interleukin 6 production in a mouse bone marrow-derived mast cell line and a malignant subline. Exp Hematol. 1990; 18(8):873-7. View

15.

Matsuda T, Hirano T, Kishimoto T . Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur J Immunol. 1988; 18(6):951-6. DOI: 10.1002/eji.1830180618. View

16.

Frei K, Leist T, Meager A, Gallo P, Leppert D, Zinkernagel R . Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients. J Exp Med. 1988; 168(1):449-53. PMC: 2188985. DOI: 10.1084/jem.168.1.449. View

17.

Boxman I, Lowik C, Aarden L, Ponec M . Modulation of IL-6 production and IL-1 activity by keratinocyte-fibroblast interaction. J Invest Dermatol. 1993; 101(3):316-24. DOI: 10.1111/1523-1747.ep12365474. View

18.

Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie P, Rubira M . Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986; 83(24):9679-83. PMC: 387204. DOI: 10.1073/pnas.83.24.9679. View

19.

Roodman G, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A . Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992; 89(1):46-52. PMC: 442817. DOI: 10.1172/JCI115584. View

20.

Kohase M, May L, Vilcek J, Sehgal P . Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell. 1986; 45(5):659-66. DOI: 10.1016/0092-8674(86)90780-4. View